Tacalyx is a privately held biotech company focused on the discovery and development of Tumour Associated Carbohydrate Antigen (TACA) antibodies for the treatment of cancer. The company is advancing a proprietary technology platform to exploit TACAs as novel targets for antibody-based therapies, including antibody drug conjugates (ADCs) and other modalities, and is building a differentiated pipeline of programmes.
Investment Rounds
Capital activity and funding progression
Industries
Frequently Asked Questions
Where is Tacalyx located?
Tacalyx is located in Berlin, Germany.
What industries does Tacalyx operate in?
Tacalyx operates in the following industries: biotechnology, oncology, drug discovery.
When was Tacalyx founded?
Tacalyx was founded on 2026-05-01.
How much total funding has Tacalyx raised?
Tacalyx has raised a total of $11,000,000.
Who are the investors in Tacalyx?
The investors in Tacalyx are: Boehringer Ingelheim Venture Fund, Kurma Partners.
What is the primary focus of Tacalyx?
Tacalyx is a biotechnology company that focuses on the discovery and development of cancer therapeutics targeting Tumor Associated Carbohydrate Antigens, also known as TACAs.
When was Tacalyx founded and where is it based?
Tacalyx was founded in 2019 as a spin-out from the Max-Planck-Institute of Colloids and Interfaces, and the company is based in Germany.
What technology does Tacalyx use to treat cancer?
Tacalyx utilizes a proprietary platform to identify and generate high-affinity antibodies against TACAs, which can be developed into various antibody-based therapies, including antibody drug conjugates.
Why are TACAs important for the research conducted by Tacalyx?
TACAs are distinctive carbohydrate structures that are uniquely expressed or overexpressed on tumor cells and play significant roles in tumor progression, such as metastasis and immune evasion, making them attractive but previously difficult-to-target structures for cancer treatment.